Abbott's Humira Letter Needed FDA's Green Light, Jury Told

Law360, Chicago (April 25, 2013, 7:20 PM EDT) -- At a trial over claims that AbbVie Inc. and Abbott Laboratories failed to warn about Humira's risks, an AbbVie regulatory director testified Thursday that Abbott needed regulatory approval before it could send its May 2010 letter to doctors about the arthritis drug's link to undetected infections.

Plaintiff Milton Tietz, whose wife Delores almost died of a histoplasmosis fungal infection as an alleged result of taking Humira, is accusing Abbott of dragging its feet by waiting a year and eight months to send the so-called dear healthcare...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.